ArticleScientific reports2025
Zhilong Huoxue Tongyu capsule inhibits hypertensive myocardial fibrosis via balancing TGF-β1/Smad3/Erbb4-IR/miR-29b pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Zhilong Huoxue Tongyu capsule (ZL) is wildly used as a Chinese patent medicine for the treatment of cardiovascular diseases. Clinical studies have found that it can significantly improve hypertension and heart failure. However, its precise molecular mechanisms remain incompletely understood. The aim of this study was to investigate the effect of ZL on myocardial fibrosis (MF) in in vivo and its potential mechanisms. We established a hypertensive MF model by subcutaneous pumping of angiotensin II (Ang II) into mice, and validated in vivo whether ZL can reduce systolic blood pressure (SBP) and inhibit MF, including the use of echocardiography and various pathological staining techniques. Mechanistically, Western blot, qRT-PCR, and various immunostaining techniques were used to verify whether ZL can regulate TGF-β1/Smad3/Erbb4-IR/miR-29b pathway, and in vivo overexpression of Erbb4-IR was used to clarify whether it plays a key role in this pathway. ZL significantly reduced SBP in hypertensive MF mice, improved cardiac function and MF. Deposition of various collagen, expression of inflammatory factors, and activation of TGF-β1/Smad3 pathway is inhibited due to the intervention of ZL. In addition, ZL significantly reduced expression of Erbb4-IR and increased the expression of miR-29b. Mechanistically, after overexpression of Erbb4-IR in vivo, the regulatory effect of ZL on TGF-β1/Smad3/Erbb4-IR/miR-29b was reversed. Our results initially demonstrated ZL could exert cardioprotective effects in hypertensive MF mice. The pharmacological mechanism of ZL may be related to its regulation on TGF-β1/Smad3/Erbb4-IR/miR-29b pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.